HUTCHMED (China) (HMDCF) Asset Utilization Ratio (2019 - 2021)

HUTCHMED (China)'s (HMDCF) quarterly Asset Utilization Ratio came in at 0.27 in Q2 2021, down 21.21% quarter-over-quarter from 0.34 in Q1 2021.

Analysis

HUTCHMED (China) (HMDCF) Asset Utilization Ratio (2019 - 2021) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported Asset Utilization Ratio for 2 consecutive years, with 0.27 the latest figure, recorded in Q2 2021.

On a quarterly basis, Asset Utilization Ratio changed N/A year-over-year to 0.27 in Q2 2021; TTM through Jun 2021 was 0.27, a N/A change from a year earlier, with the FY2022 full-year figure at 0.36, up 4.52% from the prior year.
Asset Utilization Ratio was 0.27 for Q2 2021 at HUTCHMED (China), down from 0.34 in the prior quarter.
Over five years, Asset Utilization Ratio peaked at 0.45 in Q4 2019 and troughed at 0.27 in Q2 2021.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Amgen	211.51 Bn	197.52 Bn	7.24 Bn	0.40
2	Gilead Sciences	181.48 Bn	178.30 Bn	6.22 Bn	0.58
3	Vertex Pharmaceuticals	132.45 Bn	124.60 Bn	2.84 Bn	0.47
4	Regeneron Pharmaceuticals	82.87 Bn	74.88 Bn	3.93 Bn	0.38
5	Argenx Se	61.59 Bn	56.41 Bn	1.37 Bn	-
6	Moderna	54.72 Bn	49.59 Bn	52.00 Mn	0.20
7	Alnylam Pharmaceuticals	34.13 Bn	30.82 Bn	992.69 Mn	0.90
8	Biogen	31.29 Bn	30.01 Bn	1.96 Bn	0.33
9	Roivant Sciences	30.31 Bn	30.31 Bn	1.16 Mn	0.00
10	HUTCHMED (China)	376.85 Mn	391.04 Mn	-	-

Historic Data

Download Data